Eric Swayze Sells 6,179 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Eric Swayze sold 6,179 shares of the firm’s stock in a transaction that occurred on Friday, January 30th. The shares were sold at an average price of $82.93, for a total transaction of $512,424.47. Following the completion of the sale, the executive vice president directly owned 47,747 shares in the company, valued at approximately $3,959,658.71. This trade represents a 11.46% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Eric Swayze also recently made the following trade(s):

• On Friday, January 16th, Eric Swayze sold 49 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $75.97, for a total value of $3,722.53.
• On Friday, January 16th, Eric Swayze sold 9,884 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $75.34, for a total transaction of $744,660.56.
• On Friday, January 2nd, Eric Swayze sold 23,463 shares of Ionis Pharmaceuticals stock. The stock was sold at an average price of $79.12, for a total transaction of $1,856,392.56.

Ionis Pharmaceuticals Stock Performance

IONS stock traded up $0.40 during trading on Monday, hitting $83.07. The company had a trading volume of 1,788,929 shares, compared to its average volume of 2,332,586. The firm has a market cap of $13.45 billion, a PE ratio of -49.15 and a beta of 0.29. The company has a quick ratio of 2.78, a current ratio of 2.79 and a debt-to-equity ratio of 0.96. The firm has a 50-day moving average price of $80.34 and a 200-day moving average price of $66.84. Ionis Pharmaceuticals, Inc. has a 1-year low of $23.95 and a 1-year high of $86.15.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Large investors have recently made changes to their positions in the business. Golden State Wealth Management LLC raised its holdings in shares of Ionis Pharmaceuticals by 198.4% in the 3rd quarter. Golden State Wealth Management LLC now owns 376 shares of the company’s stock worth $25,000 after purchasing an additional 250 shares in the last quarter. Steigerwald Gordon & Koch Inc. acquired a new position in Ionis Pharmaceuticals in the third quarter worth approximately $25,000. Mather Group LLC. bought a new position in shares of Ionis Pharmaceuticals in the third quarter valued at $27,000. Quarry LP acquired a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter valued at $38,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in shares of Ionis Pharmaceuticals during the 4th quarter valued at $47,000. Institutional investors own 93.86% of the company’s stock.

Analyst Ratings Changes

IONS has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Ionis Pharmaceuticals in a report on Thursday, January 22nd. Needham & Company LLC raised their price objective on Ionis Pharmaceuticals from $78.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Oppenheimer increased their target price on Ionis Pharmaceuticals from $84.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 8th. HC Wainwright upped their price target on shares of Ionis Pharmaceuticals from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Finally, Royal Bank Of Canada upped their target price on shares of Ionis Pharmaceuticals from $82.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Ionis Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $86.45.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company’s proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis’ pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.